Eaton Vance Worldwide Health Sci A
Two International Place Boston MA 02110
Map
Phone: 800-262-1122
| Category: | Health | | Fund Family: | Eaton Vance | | Net Assets: | 689.00M | | Year-to-Date Return: | 6.99% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 26-Jul-85 |
|
Samuel D. Isaly
Lead Manager since
26-Jul-85 | | | Isaly is a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. |
| Min Initial Investment: | $1,000 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $50 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $50 |
|
| |
| The investment seeks long-term capital growth. The fund invests at least 80% of net assets in securities (primarily common stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care, and medical equipment and supplies. It may invest in fixed-income securities of health sciences companies. The fund invests in foreign securities and normally invests in issuers located in at least three different countries. |
| Last Dividend
(5-Nov-85):
| 0.01 | | Last Cap Gain
(23-Dec-08):
| 1.35 | | Annual Holdings Turnover
| 54.00% | | Average for Category:
| 134.89% |
|
| Expense | ETHSX | Category
Avg | | Total Expense Ratio: | %
| 1.91% | | Max 12b1 Fee: | %
| N/A | | Max Front End Sales Load: | 5.75%
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $719 | | 5 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $1,076 | | 10 Yr Expense Projection*: |
$ YFT_NOT_APPLICABLE_ABBREVIATION | $2,105 |
|
|
0.02% Nasdaq 0.00%
Profile
